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Abstract
Background: Rwanda is a central African country with about 12 million inhabitants. The 1994 genocide against the
Tutsi destroyed much of the infrastructure, including the health system. Although this has improved significantly,
many challenges remain to be addressed. In this study, the prevalence of serological markers of past and ongoing
hepatitis B virus (HBV) infection and HBV vaccine related immunity was investigated in samples from blood donors
from all regions of Rwanda.
Methods: The results from hepatitis B surface antigen (HBsAg) analyses of all (45,061) blood donations collected
countrywide in 2014 from 13,637 first time and 31,424 repeat blood donors were compiled. Samples from 581
HBsAg negative blood donors were selected for further analysis for antibodies against HBV, anti-HBs and anti-HBc.
Additional 139 samples from HBsAg positive donors were analyzed for HBeAg/anti-HBe (132 samples) and for HBV
DNA. The S-gene was amplified by PCR, products sequenced, and phylogenetic analysis was performed.
Results: HBsAg was found in 4.1% of first time donors with somewhat higher prevalence among those from the
Central and Eastern regions than from other parts of the country. Indications of past infection was found in 21% of
the HBsAg negative donors, 4.3% had only anti-HBs suggesting HBV vaccination. HBeAg was detected in 28 (21%),
anti-HBe in 97 (73%), and both HBeAg and anti-HBe in 4 of 132 HBsAg positive donors. HBV DNA was found in 85
samples, and the complete S-gene was sequenced in 58 of those. Phylogenetic analysis of the sequences revealed
that all HBV strains belonged to subgenotype A1, and formed one clade in the phylogenetic tree. In addition, 12
strains from first time donors had a unique 18 amino acid deletion in the N-terminal part of the pre-S2 region.
Conclusion: This study indicated that the prevalence of hepatitis B is intermediate in Rwanda and that the
vaccination coverage is relatively low in young adults. All surveyed Rwandan blood donors were infected with
similar subgenotype A1 strains, and a high frequency of those with anti-HBe had detectable HBV DNA. Several
strains had in addition a unique pre-S2 deletion, the virulence of which needs to be further studied.
Keywords: HBV prevalence, HBV DNA, Pre-S mutants, Blood donors, Sub-Saharan Africa
* Correspondence: helene.norder@gu.se
1Department of Microbiology & Clinical Virology, Institute of Biomedicine at
Sahlgrenska Academy, University of Gothenburg, Guldhedsgatan 10B, 41346
Gothenburg, Sweden
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Twagirumugabe et al. BMC Infectious Diseases  (2017) 17:32 
DOI 10.1186/s12879-016-2149-z
Background
Hepatitis B virus (HBV) is a small DNA virus belonging
to the Hepadnaviridae family [1]. Its DNA encodes for
four overlapping open-reading frames, S, P, C and X [2].
The S-gene encodes for the surface proteins, preS1,
preS2 and S (HBsAg); the C-gene for the nucleocapsid,
and the pre-C/C region for the hepatitis B e antigen
(HBeAg). The X protein is implicated in transactivation
of the transcription of the HBV proteins and may play a
role in carcinogenesis. The P-region encodes for a DNA-
polymerase with reverse transcriptase and RNAse func-
tion, and the terminal protein, tp [1].
The viral pregenomic RNA is reverse transcribed to a
partially double-stranded DNA by the viral polymerase,
which by replication errors introduce mutations in the
viral genome. Some of these mutations have become
fixed and HBV has with time evolved into nine differ-
ent genotypes (A-I) [1, 3]. Most of the genotypes are
further genetically classified into subgenotypes. Geno-
types A (subgenotypes A1, A3–A7), D (subgenotypes
D1, D2, D4, and D6–D8) and E are prevalent in African
countries [1, 4, 5].
Irrespective of genotype, early stages of HBV infec-
tion are usually asymptomatic and often unrecognized
[6]. The risk for chronic infection increases inversely to
the age of the patient at the moment of infection.
Chronically infected patients have 15–60% lifetime risk
for liver cirrhosis, liver failure and/or hepatocellular
carcinoma [6–8]. Approximately 600,000 individuals
die annually from complications of the infection [9, 10].
Currently, more than 2 billion people worldwide have
been infected by HBV including almost 240 million
with chronic infection. More than 50% of the chronic-
ally infected individuals live in Asia and in Sub-Saharan
Africa where the prevalence among adults is estimated
to 5–10% [4, 7].
In the natural history of chronic HBV infection,
seroconversion from HBeAg to anti-HBe is a favor-
able sign usually accompanied by a decrease in HBV
replication and remission of hepatitis [11]. However,
for some patients the infecting virus strain mutate in
the pre-core region to form the so-called pre-core
mutant [12] or in the basal core promoter region
[13, 14]. Patients infected with these mutants often
have active liver disease with elevated HBV DNA
levels in serum also after seroconversion to anti-HBe
[15, 16]. The pre-core mutation occurs in almost all
genotypes and subgenotypes of HBV, but rarely in
subgenotypes A2, C1, F2, F3 and H [1, 16–18], and
the basal pre-core mutations have been described
from most genotypes [19, 20].
To date, there are no anti-viral compounds that com-
pletely cure HBV infection [21]. An efficacious vaccine
was developed in the 1980s. Since 1991, the WHO has
recommended that HBV vaccination should be included
in the child vaccination program globally. Countries
that have implemented this policy more than two
decades ago have a substantial decline of the HBV
prevalence [22]. However, the infection remains a major
health burden in highly endemic zones including sub-
Saharan Africa [23].
Rwanda introduced universal vaccination of children
against HBV in 2003, as part of its substantial recon-
struction of the infrastructure of the health system after
the 1994 genocide against Tutsis. The prevalence of
HBV is still significant in the adult population, and has
been estimated to be about 5% based on studies on small
patient groups [24–26] and on data from neighboring
countries [23, 27].
The aims of this study were to evaluate the prevalence
of past and current HBV infection among blood donors
in all five regions of Rwanda, and to determine the gen-
etic variability and the geographical distribution of HBV
strains circulating in the country.
Methods
Blood donors and serum samples
Data were aggregated on analyses for HBsAg in sam-
ples from all voluntary non-remunerated first time
and repeat blood donors in Rwanda recruited
county-wide from five different Regional Centers for
Blood and Transfusion during 2014 (Fig. 1). In total,
there were 45,061 blood donors including 13,637 first
time donors and 31,424 repeat donors (Table 1). All
samples were routinely analyzed within 24 h after collec-
tion at the National Center for Blood and Transfusion
(NCBT)-Kigali for HBsAg, anti-HCV, HIV1/2 and syphilis.
The analysis for HBsAg was performed by chemilumines-
cent microparticles immunoassay (CMIA) using HBsAg
qualitative II assay by Abbott Laboratories (Abbott
Park, IL, USA) on ARCHITECT i2000SR platform ac-
cording to the instructions of the manufacturer. The
results of the analyses were manually transferred to a
register. This register was used for selection of the
samples for this study.
All serum samples from blood donors are stored
frozen at the NCBT-Kigali, and all of those with ≥
2 mL serum from HBsAg positive first time and re-
peat blood donors and from about four times more
HBsAg negative donors were obtained for further
analyses. Since only 515 samples from donors sam-
pled in 2014 were available (101 of those were HBsAg
positive at NCBT-Kigali), an additional 205 samples
from donors collected in January and February 2015
were included (35 of those were HBsAg positive at
NCTB) A simplified schematic figure of the samples
used for further analysis is given in Fig. 1. Only HIV
negative blood donors were selected for the study.
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All samples were stored at −70 °C until transportation
to the Clinical Microbiology Laboratory (CML) at
Sahlgrenska University Hospital, Gothenburg, Sweden,
for analyses. The samples were transported on dry ice
and arrived at CML within 16–18 h where they were
kept at −70 °C until analyzed.
Analysis for HBsAg, anti-HBc, anti-HBs, HBeAg, anti-HBe,
and anti-HDV at CML, Sweden
At the CML, all samples were re-analyzed by CMIA for
HBsAg using ARCHITECT HBsAg (Abbott Laboratories,
IL,USA) on ARCHITECT i4000SR platform according to
the instructions of the manufacturer.
Fig. 1 Flowchart of samples selected for further analysis in this study
Table 1 Origin, gender and presence of HBsAg in all 45,061 blood donors in Rwanda sampled in 2014
All blood donors HBsAg positive blood donors
Origin Category of donors Males N (%)a Females N (%)a Total N (%)a Males N (%)b Females N (%)b Total N (%)b
Eastern Province First time donors 961 (2.1) 516 (1.1) 1 477 (3.3) 57 (5.9) 27 (5.2) 84 (5.7)
Repeat donors 2 314 (5.1) 547 (1.2) 2 861 (6.4) 16 (0.7) 2 (0.36) 18 (0.6)
Subtotal 3 275 (7.3) 1 063 (2.4) 4 338 (9.6) 73 (2.2) 29 (2.7) 102 (2.4)
Kigali City First time donors 2 326 (5.2) 1 002 (2.2) 3 328 (7.4) 138 (5.9) 37 (3.7) 175 (5.3)
Repeat donors 13 424 (29.8) 2 727 (6) 16 151 (35.8) 6 (0.0) 2 (0.1) 8 (0.1)
Subtotal 15 750 (35) 3 729 (8.3) 19 479 (43.2) 144 (0.9) 39 (1.0) 183 (0.9)
Northern Province First time donors 1 618 (3.6) 523 (1.2) 2 141 (4.7) 82 (5.1) 12 (2.3) 94 (4.4)
Repeat donors 4 550 (10.1) 392 (0.9) 4 942 (11) 2 (0.0) 1 (0.3) 3 (0.1)
Subtotal 6 168 (13.7) 915 (2.0) 7 083 (15.7) 84 (1.4) 13 (1.4) 97 (1.4)
Southern Province First time donors 2 144 (4.8) 1 865 (4.2) 4 009 (8.9) 90 (4.2) 29 (1.6) 119 (3.0)
Repeat donors 3 319 (7.4) 1 753 (34.6) 5 072 (11.3) 2 (0.1) 1 (0.1) 3 (0.1)
Subtotal 5 463 (12.1) 3 618 (3.9) 9 081 (20.2) 92 (1.7) 30 (0.8) 122 (1.3)
Western Province First time donors 1 577 (3.5) 1 105 (2.4) 2 682 (6) 70 (4.4) 16 (1.4) 86 (3.2)
Repeat donors 1 642 (3.6) 756 (1.7) 2 398 (5.3) 1 (0.1) 0 (0) 1 (0.0)
Subtotal 3 219 (7.1) 1 861 (4.1) 5 080 (11.3) 71 (2.2) 16 (0.9) 87 (1.7)
Total First time donors 8 626 (19.1) 5 011 (11.1) 13 637 (30.3) 437 (5.1) 121 (2.4) 558 (4.1)
Repeat donors 25 249 (56.1) 6 175 (13.7) 31 424 (69.7) 27 (0.1) 6 (0.1) 33 (0.1)
Total 33 875 (75.2) 11 186 (24.8) 45 061 (100.0) 464 (1.4) 127 (1.1) 591 (1.3)
a = percentage of all donation (45 061)
b = percentage of HBsAg positive of all donors of respective sex and region
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The samples were also analyzed with CMIA for anti-
HBs and total anti-HBc using ARCHITECT anti-HBs
and ARCHITECT anti-HBc II (Abbott Laboratories, IL,
USA), respectively on the ARTCHITECT i4000SR ma-
chine following the manufacturer’s instructions. HBsAg
positive samples were further analyzed for HBeAg and
anti-HBe with the ARCHITECT HBeAg and ARCHI-
TECT anti-HBe (Abbott Laboratories, IL, USA) assays.
All HBsAg positive and isolated anti-HBc-positive sam-
ples were analyzed for antibodies against hepatitis delta
virus (anti-HDV) with the ETI-AB-DELTA K-2 kits
(Diasorin, Saluggia, Italy) according to the instructions
by the manufacturer.
HBV DNA extraction
Nucleic acids were extracted from 200 μL of serum
from each HBsAg and isolated anti-HBc positive sam-
ple using the NucliSens EasyMag automated extractor
and kit (BioMerieux, Marcy l’Etoile, France), according
to the manufacturers’ instructions. The nucleic acids
were eluted in 110-μL nuclease free sterile water.
qPCR for HBV DNA detection
The extracted nucleic acids were analyzed for HBV
DNA by a TaqMan qPCR assay targeting the S region
with primers HBV305S GCCAAAATTCGCAGTCCC,
HBV460AS GATARTCCAGAAGAACCAAYAAGAAG
and HBV-probe FAM-CGCGCGATGAGGCATAGCA
GYAGGATRAARAACGCGCG-BHQ1. Each 25 μl reac-
tion mix contained 5 μl of extracted DNA, 12.5 μl 2x
universal master mix/MgCl2 and Platinum One-Step
Quantitative RT-PCR System with ROX (Invitrogen,
Carlsbad, CA, USA), and 0.5 μM of each primer and
0.4 μM probe. The amplification profile on Applied Bio-
systems 7300 platform (Carlsbad, CA, USA) was per-
formed by initial denaturation at 95 °C for 10 min
followed by 45 cycles at 95 °C for 15 s, 55 °C for 15 s
and 72 °C for 30 s. RNA/DNAse-free water was used as
negative control. Serial 10-fold dilutions (1/10 – 1/100
000) of two sera with 1.0 × 108 and 1.2 × 108 IU HBV
DNA/mL, respectively, were used in each assay as positive
controls and for approximate estimation of the HBV DNA
concentrations of the samples investigated. The amount
of HBV DNA in the positive control samples had previ-
ously been quantified by COBAS® AmpliPrep/COBAS®
TaqMan® HBV Test, v2.0 (Roche AG, Basel, Switzerland).
Patient samples with ct values above 42, corresponding to
less than 4 IU HBV DNA/mL were considered as negative,
and samples with ct values less than 23 were considered
as having >5 × 108 IU/mL, due to limitations in the
standardization of the assay, making extrapolations uncer-
tain. The lowest Ct values of the control samples varied
from ct 25 to ct28 in the assays.
PCR amplification of the S-gene for sequencing
A semi-nested PCR was performed to amplify the
complete S-gene in a 50 μl reaction mix with 5 μl ex-
tracted nucleic acids as template. The PCR mix con-
tained 31.9 μl of RNase-free H2O (Sigma), 1x Taq buffer
(Applied Biosystems, Carlsbad, CA, USA), 3 mM MgCl2
(Applied Biosystems, Carlsbad, CA, USA), 0.2 mM
dNTP, 0.3 mM of each primer, and 1 U of Taq polymer-
ase. Pooled primers gtA1-2792S1 /gtA1-356AS1 were
used for the first round PCR (Additional file 1 Table S1).
The PCR reaction was performed with initial denatur-
ation at 95 °C for 3 min followed by 40 cycles with 94 °C
for 30 s, 60 °C for 60 s and 72 °C for 60 s, and one cycle
at 72 °C for 10 min. Three μl of the first round product
were used as template in the second amplification round
with primers gtA1-2809S2 /gtA1-356AS2 (Additional
file 1 Table S1) and 2.75 mM MgCl2. Deletions and rare
mutations observed were confirmed by amplifying the
complete S-gene with a semi-nested PCR using primer
pools HBV-2730S and HBV-874R in the first PCR and
semi-nest the product obtained in three reactions with
primers HBV2730S and HBV-98R, HBV-3125S and
HBV-548R, and HBV-464S and HBV-874R (Additional
file 1 Table S1). The PCR reactions were performed as
the PCR reaction described above, with modification of
the annealing temperature to 59 °C.
Sequencing
All amplified PCR products were purified and extracted
with QIAquick PCR Purification Kit (Qiagen; Hilden,
Germany) according to the manufacturer’s description.
The purified products were cycle sequenced in both di-
rections by using 1.6 μM of the same primers as in the
nested PCR in the BigDye Terminator Cycle Sequen-
cing Ready Reaction kit (Applied Biosystems) according
to the manufacturer’s instructions. The sequences were
obtained by the 3130 × l Genetic Analyzer (Applied Bio-
systems, Carlsbad, CA, USA).
Phylogenetic analysis
The sequences obtained were analyzed in the SeqMan
program in the DNAStar programme package version
10.1.2 (DNA Star Inc, Madison, WI 53705, USA). The
sequences were aligned with the corresponding region of
641 sequences representing all HBV genotypes obtained
from GenBank, including 252 genotype A strains from
Africa. Phylogenetic analysis was carried out with the
PHYLIP package version 3.65. Evolutionary distances
were calculated using the F84 algorithm in the DNA-
DIST program with a transition/transversion ratio of
1.53 with gamma correction with alpha 0.28. Phylogen-
etic trees were constructed using the unweight pair-
group method using arithmetic averages (UPGMA) and
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the neighbor-joining method in the NEIGHBOR pro-
gram in the PHYLIP package. Bootstrap analysis for
1,000 replicas was performed with the SEQBOOT and
CONSENSE programs in the PHYLIP package.
HBsAg subtype determination
The HBsAg subtypes of the strains were determined
from the deduced amino acid sequences based on
the residues at positions 122, 127 and 160 of the
small S-gene [28].
Statistical analysis
GraphPad Prism Version 6.0 g was used to compare
the prevalence of HBV with origin and group of do-
nors using the Chi-square test with Yates correction.
Multivariate binary logistic regression was performed
to compare the characteristics of donors with and
without HBeAg adjusting for age, gender, origin, cat-
egory of donors and viral load. This was also per-
formed for donors with and without an 18 amino acid
deletion in preS2. The Odds Ratio (OR) were used to
express results with 95% confidence intervals (CI 95%),
and p-values <0.05 were considered statistically signifi-
cant. All analyses were performed using SPSS 22.0
(IBM, Chicago, USA).
Results
There were about three times more males than females
among the 45,061blood donors sampled during 2014 in
five different regions of Rwanda, and most, 43%, origi-
nated from Kigali city (Table 1). The majority (70%) of
the donors were repeat donors.
HBsAg was identified in sera from 558 of 13,657
(4.1%) first time donors and in 33 out of 33,424 (0.1%)
repeat donors (Table 1; Fig. 1). The highest HBsAg
prevalence among the first time blood donors was ob-
served in the Eastern Province (5.3%), Kigali City (5.3%)
and the Northern Province (4.4%) compared to the
Southern and Western Provinces, where the HBsAg
prevalence was respectively 3.0 and 3.2% (p <0.001, OR:
1.69 [1.42-2.02]; Table 1).
The geographical distribution of the 720 blood do-
nors from whom samples were obtained for further
analyses did not mirror the geographical distribution
of all blood donors from 2014 (Table 2). There were
relatively more samples obtained from the Eastern
Province (n = 182; 25%), from where only 9.6% of all
donors originated during 2014. In addition, 43% of all
persons donating blood in 2014 were from Kigali
City, while only 9.3% of the 720 samples obtained
were from blood donors from this region (Table 2).
Furthermore, about half of the samples obtained
Table 2 Origin, gender and presence of HBsAg in 720 blood donors sampled in 2014 and 2015 and obtained for this study
Samples obtained for study HBsAg positive —samples used in this study
Region Category of donors Males N (%)a Females N (%)a Total N (%)a Males N (%)b Females N (%)b Total N (%)b
Eastern Province First time donors 72 (10) 11 (1.5) 83 (11.5) 45 (6.3) 5 (0.7) 50 (7)
Repeat donors 88 (12.2) 11 (1.5) 99 (13.8) 2 (0.3) 0 (0) 2 (0.3)
Subtotal 160 (22.2) 22 (3.1) 182 (25.3) 47 (6.5) 5 (0.7) 52 (7.2)
Kigali City First time donors 44 (6.1) 9 (1.3) 53 (7.4) 9 (1.3) 0 (0) 9 (1.3)
Repeat donors 10 (1.4) 4 (0.6) 14 (1.9) 0 (−) 0 (−) 0 (0)
Subtotal 54 (7.5) 13 (1.8) 67 (9.3) 9 (1.3) 0 (0) 9 (1.3)
Northern Province First time donors 56 (7.8) 13 (1.8) 69 (9.6) 19 (2.6) 1 (0.1) 20 (2.8)
Repeat donors 74 (10.3) 10 (1.4) 84 (11.7) 2 (0.3) 0 (0) 2 (0.3)
Subtotal 130 (18.1) 23 (3.2) 153 (21.2) 21 (2.9) 1 (0.1) 22 (3.1)
Southern Province First time donors 79 (11) 31 (4.3) 110 (15.3) 25 (3.5) 8 (1.1) 33 (4.6)
Repeat donors 119 (16.5) 29 (4) 148 (20.6) 2 (0.3) 1 (01) 3 (0.4)
Subtotal 198 (27.5) 60 (8.3) 258 (35.8) 27 (3.8) 9 1.3) 36 (5)
Western Province First time donors 46 (6.4) 6 (0.8) 52 (7.2) 15 (2.1) 4 0.6) 19 (2.6)
Repeat donors 8 (1.1) 0 (0) 8 (1.1) 1 (0.1) 0 (0) 1 (0.1)
Subtotal 54 (7.5) 6 (0.8) 60 (8.3) 16 (2.2) 4 0.6) 20 (2.8)
Total First time donors 297 (41.2) 70 (9.7) 367 (51) 113 (15.7) 18 (2.5) 131 (18.2)
Repeat donors 299 (41.5) 54 (7.5) 353 (49) 7 (1) 1 (0.1) 8 (1.1)
Total 596 (82.8) 124 (17.2) 720 (100) 120 (16.7) 19 (2.6) 139 (19.3)
a = percentage of all samples obtained
b = percentage of all HBsAg positive donors of respective sex and region in 2014
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(51%) were from first time donors, while this group
was represented by only 30% of all donors in 2014.
Re-analysis for HBsAg
On re-analyzing 720 blood donor samples for HBsAg at
CML in Sweden, nine of 136 HBsAg positive samples at
NCBT in Rwanda were repeatedly non-reactive for
HBsAg, and none of them were reactive for anti-HBc or
anti-HBs, indicating that these samples were false posi-
tive in Rwanda. Also, there were 12 of 584 primarily
HBsAg negative at NCBT that turned repeatedly reactive
for HBsAg at CML. Nine of these samples were from
first time donors, and all but one were positive for anti-
HBc including one also positive for anti-HBs. Three of
these were reactive for HBeAg and 7 for anti-HBe. The
anti-HBc negative sample did not have any other marker
for HBV infection, and may have had false reactivity for
HBsAg at CML, which gives a false positive rate of 0.8%
at CML and a 1.9% false negative rate of the test at
NCBT-Kigali. The reason for this discrepancy may either
be, as for two samples, a low HBsAg reactivity that was
missed at NCBT in Rwanda, or a mistake in the manual
transfer of the laboratory results into a register of the
blood donors at NCBT.
In total there were thus 139 HBsAg positive samples
and 581 HBsAg negative samples that were further ana-
lyzed for HBV markers (Table 3). Most of the HBsAg
positive blood donors were first time donors and found
in all age groups, however, 43.2% were younger than
26 years (Table 4).
HBeAg and anti-HBe
Of the 139 HBsAg positive samples, 131 (95%) could
be analyzed for both HBeAg and anti-HBe, and one
additional sample could only be analyzed for HBeAg
(Table 3). HBeAg was found in 28 (21%) samples and
anti-HBe in 97 (73%); four (3%) of the samples had
both markers; and three (2.3%) lacked both HBeAg
and anti-HBe (Table 3). There was a tendency of
HBeAg-positive donors being younger (mean age of
25.2 +/− 6.2 years) than HBeAg-negative donors (mean
age 29.8 +/− 7.6 years). This age difference was, however,
not significant (OR = 0.920 [0.843-1.003], p = 0.059)
(Additional file 1 Table S2). There was in addition no
significant association between HBeAg reactivity and
gender, category of donors or province of origin
(Additional file 1 Table S2).
Anti-HBc and anti-HBs
All but one of the 139 HBsAg positive samples had de-
tectable anti-HBc. Among the 581 HBsAg negative sam-
ples, 136 (23%) had detectable anti-HBc; 122 (90%) of
these had also anti-HBs (Tables 3, 4). Fourteen blood do-
nors, all male, had isolated anti-HBc, and 25 (4.3%) had
isolated anti-HBs with mean anti-HBs titers of 355 mIU/
mL (range 10 - >1000 mIU/mL). The donors with anti-
HBs alone originated from all regions of Rwanda and
were 21–45 years old.
HDV coinfection or superinfection
Analysis for anti-HDV was performed in 134 of the 139
HBsAg positive samples and in 11 of the 14 samples
with isolated anti-HBc. All samples were negative for
this marker.
HBV DNA detection
HBV DNA was detected by qPCR in 85 (61%) of the 139
HBsAg positive samples, and in none of the 14 samples
with isolated anti-HBc (Table 3). Almost all of the
HBeAg positive samples (27/28; 96%) and 48/97 (49%)
anti-HBe positive samples had detectable HBV DNA
(Table 3). HBV DNA was also detected in all four sam-
ples with both HBeAg and anti-HBe and in none of the
three samples lacking both these HBe-markers.
The HBV DNA levels, given as IU/mL based on the
serial dilutions of the two positive sera were higher in
Table 3 Gender and type of donor in relation to presence of HBsAg, HBeAg, anti-HBe, HBV DNA, anti-HBs and anti-HBc as markers
for past infection and anti-HBs alone as indication of HBV vaccination
First time donors Repeat donors All donors
Presence of marker Males Females All Males Females All Males Females All
HBsAg (% of all 720 samples obtained) 113 (15.7) 18 (2.5) 131 (18.2) 7 (1.0) 1 (0.1) 8 (1.1) 120 (16.7) 19 (2.6) 139 (19.3)
HBeAga (% of 132 HBsAg positive samples) 27 (20.5) 4 (3.0) 31 (23.5) 1 (0.8) 0 1 (0.8) 28 (21.2) 4 (3.0) 32 (24.2)
Anti-HBeb (% of 131 HBsAg positive samples) 82 (62.6) 14 (10.7) 96 (73.3) 5 (3.8) 1 (0.8) 6 (4.6) 87 (66.4) 15 (11.4) 102 (77.9)
HBV DNA and HBeAg (% of HBeAg positive samples) 26 (96.3) 4 (100) 30 (96.8) 1 (100) 0 1 (100) 27 (96.4) 4 (100) 31 (96.9)
HBV DNA and anti-HBe (% of anti-HBe positive samples) 40 (48.8) 11 (78.6) 51 (53.1) 2 (40) 0 2 (33) 42 (48.3) 11 (73.3) 53 (52.0)
All with HBV DNA (% of 139HBsAg positive samples) 67 (48.2) 15 (10.8) 82 (59.0) 3 (2.2) 0 3 (2.2) 70 (50.4) 15 (10.8) 85 (61.2)
Anti-HBs and anti-HBc (% of 581 HBsAg negative) 37 (0.6) 11 (1.9) 48 (8.3) 66 (11.4) 8 (1.4) 74 (12.7) 103 (17.7) 19 (3.3) 122 (21)
Anti-HBs lacking anti-HBc (% of 581 HBsAg negative) 9 (1.5) 3 (0.6) 12 (2) 11 (1.9) 2 (0.3) 13 (2.2) 20 (3.4) 5 (0.9) 25 (4.3)
a7 samples were not sufficient for HBeAg; b8 samples were not sufficient in material to run the anti-HBe
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HBeAg than anti-HBe positive sera with median 3.7 ×
106 vs. 500 IU HBV DNA /mL (p <0.0001). The four
samples with both HBe-markers had a median value of
4.3 × 103 IU HBV DNA /ml. There were 31 samples with
a viral load of ≥104 IU HBV DNA /ml (Additional file 1
Table S2); 22 of these samples had detectable HBeAg
(Additional file 1 Table S2).
Sequencing the S-gene
The complete S-gene could be amplified and sequenced
in 58 of the 85 HBV DNA-positive samples. Based on
the deduced amino acid sequence of the small S-gene,
the subtype was inferred to adw2 for 56 strains (97%),
since they expressed Lys122, Pro127 and Lys160. Two sam-
ples, RW14-173 and RW14-203, expressed Arg122 and
were ayw1 strains. Both these two later strains were from
first time donors, one from the Eastern and the other from
the Western Province. None of the sequenced strains had
the vaccine escape mutation Gly145/Arg/Ala.
Several mutations were observed when the pre-S re-
gions were analyzed. The most common mutations were
deletion in the pre-S1 and pre-S2 regions. Two larger
deletions in pre-S1 was identified in two strains, RW14-
219 with a deletion between amino acids 30 and 84, and
RW14-226 with a 20 amino acid deletion between resi-
dues 67 and 86. There were in addition an 18 amino acid
deletions in the N-terminal region of pre-S2, between
residues 5 and 22 in twelve strains (RW14-03, − 05, −10,
−14, −40, −41, −43, −118, −136, −173, −190, and −216).
Other deletions (9, 11 and 14 amino acids) in the same
region were observed for another three strains (RW14-
22, −198 and −222). The18 amino acid deletion in pre-
S2 was not independently associated with age or gender
of the donors, presence of HBeAg/anti-HBe, or viral
load (Additional file 1 Table S3).
Phylogenetic analysis
Based on phylogenetic analysis of the complete S-gene,
all 58 sequenced strains in this study were found to be-
long to subgenotype A1 (Fig. 2). All strains belonging to
this subgenotype formed three subclades in the phylo-
genetic tree. All but five of the strains in this study
formed one of these subclades together with previously
published strains from Kigali, Rwanda, and one strain each
from Somalia and the Democratic Republic of the Congo
(Fig. 2). The formation of this clade was supported by 68%
bootstrap value. Four of the strains from the blood donors
in Rwanda were not found in this A1 subclade, and were
more closely related to Indian, Chinese and Japanese sub-
genotype A1 isolates. Another strain, RW14-41 from a
first time donor in the Eastern Province, was divergent
and formed a separate branch within genotype A. This
strain had in addition to the large 18 amino acid deletion
in pre-S2 also several amino acid substitutions in pre-S2,
and was also divergent from the genotype A strains when
the small S-gene was analyzed.
The subgenotype A1 strains also formed separate clades
when the small S-gene was analyzed. In the clade formed
by the small S-genes of most strains from Rwanda, there
was one branch formed mainly by strains from Rwanda
together with 6 strains from Kenya. The other strains from
Rwanda were intermixed with A1 strains from other Afri-
can countries in this clade (Additional file 2 Figure S1).
Discussion
This study on HBV infections in blood donors from all
five different provinces of Rwanda confirms that this
country has intermediate endemicity for this infection,
despite its geographical location in a region of Africa with
high HBV prevalence. The prevalence of HBsAg positivity
was equal in the five regions of Rwanda, and was 4.1%
among first time blood donors. The actual HBsAg preva-
lence may differ between the regions, since the number of
first time blood donors investigated from each region did
not mirror the population size in the regions, especially
not from Kigali City. In addition, fist time donors may not
represent the general population, especially since all HIV
positive blood donors were excluded in the study. How-
ever, the HBsAg prevalence found in this study is compar-
able to that previously described from different groups of
female patients and health care workers in Kigali City
[23–26], which indicates that the results obtained from
the first time blood donors may be regarded as indicative
of the HBV prevalence in the general population.
Table 4 Distribution of donors according to HBsAg, HBeAg, anti-HBc and anti-HBs reactivity and age groupsa
HBsAg HBeAg Anti-HBs positive
Age group (years) All donors Positive N (%) N Positive N (%) N Anti-HBc positive N (%) Anti-HBc negative N (%)
18–25 263 60 (22.8) 56 20 (35.7) 203 32 (15.8) 4 (2.0)
26–35 296 51 (17.2) 49 11 (22.4) 245 52 (21.2) 15 (6.1)
36–45 130 26 (20.0) 25 1 (4.0) 104 28 (26.9) 6 (5.8)
46–55 27 2 (7.4) 2 0 (0.0) 25 8 (32.0) -
56–65 4 0 (0.0) - - 4 2 (50.0) -
Total 720 139 (19.3) 132 32 (24.2) 581 122 (21.0) 25 (4.3)
aProportions calculated with a denominator on the same row in the precedent adjacent column nN)
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Fig. 2 (See legend on next page.)
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All Rwandan children are vaccinated against HBV,
starting from six-weeks of age, since 2003, when the
pentavalent vaccine was introduced by the WHO-
sponsored Expanded Program of Immunization through
Gavi, the Vaccine Alliance. Thus, most HBV infections
are now occurring among adults. In this study, about
one quarter (23%) of the HBsAg negative blood donors,
who may be representative of the wider adult population
in the country, have been exposed to HBV and cleared
the infection. This is a relatively lower prevalence of
anti-HBc and anti-HBs compared to many other Sub-Sa-
haran African countries especially those in West Africa
[29], which suggests that a large part of the Rwandan adult
population is susceptible to hepatitis B. In addition, the
vaccination coverage seems to be low among adults in
Rwanda, with 4.3% of the blood donors in this study hav-
ing only anti-HBs, indicating immunity obtained by HBV
vaccination. This is in accordance with a study on 378
health care workers in Rwanda, among who 4.5% reported
having received the HBV vaccine [24]. There is thus a
need to implement a vaccination policy for adults in
Rwanda to reduce the number of new infections in this
predominantly sexually active population.
In Africa, HBV genotypes A, D and E are the most
prevalent [30]. The findings in this study were consistent
with this, with all Rwandan strains belonging to geno-
type A. The strains formed a separate clade among the
subgenotype A1 strains in the phylogenetic tree, and
strains from the five different regions of the country
were intermixed with each other within this clade. This
may indicate that once there was an introduction of this
strain which has spread throughout the country, and is
now the dominant HBV strain. The absence of strains of
other HBV genotypes in samples from the blood donors
is surprising, and may indicate that hepatitis B was ra-
ther recently introduced into the country. This finding is
consistent with the identified intermediate to low preva-
lence of HBV among blood donors, and the single major
clade with a common ancestor formed by the strains
from all regions of the country. Genotype D has been
reported from neighboring countries and from pregnant
HIV positive women in Kigali City, however the country
of origin of these women was not reported [31, 32]. In
this study there were few serum samples from HBsAg
positive blood donors from Kigali City, therefore other
HBV genotypes may be present in the capital of Rwanda,
even if they were not identified in this study. However,
other previously described HBV strain from Kigali were
of subgenotype A1 [31] and was found intermixed with
strains from this study in the A1 clade that was formed
only by Rwandan strains in the phylogenetic tree. A
comprehensive study on liver disease patients recruited
from different regions of the country including more pa-
tients from Kigali City may be able to determine if A1,
and especially this strain forming the A1 clade, is pre-
dominant in all HBV carriers of Rwandan nationality.
Several of the HBV strains sequenced in this study had
a large deletion in the N-terminal region of pre-S2.
These strains were interspread in the A1 clade, which in-
dicates that the deletion had occurred independently in
the strains. There was no difference between the carriers
of strains with and without this deletion with regard to
age, gender, origin, viral load, or HBeAg. The liver dis-
ease progression of the blood donors infected with
strains with and without the deletion mutant could not
be determined in this study. The impact on disease pro-
gression of these strains may be investigated by compar-
ing their prevalence in chronic HBV carriers and
patients with HBV-induced HCC and/or liver cirrhosis
in Rwanda, since such deletions have been found in pa-
tients infected by other genotypes and have developed
cirrhosis or HCC [33–36].
Complete genomes of A1 strains with and without the
deletion will reveal if this mutation predisposes for other
mutations in the HBV genome as in the promoter regions.
Sequencing strains from HBsAg positive liver disease pa-
tients from different regions of Rwanda will also reveal if
this strain is more virulent or more easily transmissible
than the other A1 strains found in this study. In addition,
more than half of the blood donors infected with anti-
HBe positive strains also had detectable HBV DNA, indi-
cating a high prevalence of the pre-core mutant or basal
core promoter mutants [37, 38]. The HBV pre-core mu-
tant strains have been shown to cause fulminant hepatitis
in the recipient when horizontally transmitted [39–41]
and found in both chronic active and inactive hepatitis
HBsAg carriers [42]. In addition, the basal core promoter
mutants have been shown to be involved in the develop-
ment of cirrhosis and HCC [43–46]. The mutations in the
Rwandan strains and their involvement in liver disease
progression in HBV carriers could not be evaluated in this
study, and need to be investigated. Further studies are
therefore needed on HBV strains from patients with differ-
ent stages of liver disease in Rwanda.
(See figure on previous page.)
Fig. 2 Phylogenetic tree based on 1212 nucleotides of the large S-gene (pre-S1/pre-S2/S) of 699 strains representing all HBV genotypes. All 252
available genotype A sequences of the large S-gene of strains from different African countries were included in the analysis. The genotypes are
indicated on the branches. The branch with 53 of the 58 A1 strains from this study and additional 7 strains from Rwanda and 21 strains from
other African countries is enlarged. The strains sequenced in this study are shown in red. Strains obtained from GenBank are given with accession
number and country of origin at the nodes. Strains with the 18 amino acid deletion in pre-S2 are marked with a red arrowhead at the node
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Conclusions
This is the first study to show an extensive prevalence of
HBV serum markers among adults in Rwanda. Further-
more, the study showed that all blood donor strains
belonged to subgenotype A1, and that there is a high
prevalence of HBV strains with several pre-S mutations
whose clinical implications need to be explored. These
data are of paramount importance for healthcare planning
for management, vaccination policy, and surveillance of
HBV infections in Rwanda.
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Additional file 2: Figure S1. Phylogenetic tree of the small S-gene
encoding for HBsAg of 527 strains. The branch with 52 of the 58 A1
strains from this study and additional 7 strains from Rwanda and 13
strains from other African countries is enlarged. The strains sequenced
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the nodes. (PPTX 93 kb)
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